ENCOLL CORP.

EnColl Corporation, established in 1994, develops, manufactures and markets high-purity Type-I collagen-based medical devices using proprietary Two-step enzyme Treatment Process (TTP) technology. The company produces surgical-grade collagen with >97% purity and charge modifications for multiple clinical applications. Product lines include Helicoll®, a bioengineered acellular dermal replacement for wound management and tissue regeneration; dermal and dental surgical products; cardiovascular and orthopedic implants; stem cell and gene therapy matrices; collagen-coated research platforms for cell culture; skincare; nutritional; and veterinary applications. EnColl's phosphorylated collagen technology achieves superior biocompatibility, minimal immunogenicity, and enhanced bioactivity compared to traditional collagen extraction methods. The company holds three U.S. patents and manufactures under FDA and WHO regulatory compliance. Applications span general and plastic surgery (wound and burn healing), orthopedic regeneration, periodontal and dental reconstruction, neurological repair, and biopharmaceutical research.